Patents by Inventor Michael Wormstone

Michael Wormstone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intraocular devices
    Patent number: 11958927
    Abstract: Described herein are methods of stereolithographically printing intraocular devices, in particular intraocular lenses, as well as stereolithographic compositions for use therein. The stereolithography composition may comprise: a photoinitiator; a monofunctional aryl acrylate monomer, wherein the acrylate group of the monofunctional aryl acrylate monomer is of the formula -0-(C?0)-CH?CH2; and a multifunctional methacrylate or acrylate cross-linker, wherein the monofunctional aryl acrylate monomer is present in the composition in a greater amount than the multifunctional methacrylate or acrylate cross-linker.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 16, 2024
    Assignee: UEA Enterprises, Limited
    Inventors: Aram Saeed, Michael Wormstone
  • Intraocular Devices
    Publication number: 20210198408
    Abstract: Described herein are methods of stereolithographically printing intraocular devices, in particular intraocular lenses, as well as stereolithographic compositions for use therein. The stereolithography composition may comprise: a photoinitiator; a mono-functional aryl acrylate monomer, wherein the acrylate group of the monofunctional aryl acrylate monomer is of the formula —0—(C?0)—CH?CH2; and a multifunctional methacrylate or acrylate cross-linker, wherein the monofunctional aryl acrylate monomer is present in the composition in a greater amount than the multifunctional methacrylate or acrylate cross-linker.
    Type: Application
    Filed: September 5, 2018
    Publication date: July 1, 2021
    Inventors: Aram Saeed, Michael Wormstone
  • TREATMENT OF FIBROTIC EYE DISORDERS USING AN MMP2 INHIBITOR
    Publication number: 20110236395
    Abstract: Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.
    Type: Application
    Filed: September 9, 2009
    Publication date: September 29, 2011
    Applicant: UNIVERSITY OF EAST ANGLIA
    Inventors: Ian Michael Wormstone, Lucy Dawes, Julie Ann Eldred, Dylan Edwards, Lisa Hodgkinson
  • TREATMENT OF FIBROTIC EYE DISORDERS
    Publication number: 20110223177
    Abstract: Inhibitors of myosin activity are used to treat or prevent a fibrotic disorder of the eye, for example posterior capsule opacification (PCO).
    Type: Application
    Filed: September 9, 2009
    Publication date: September 15, 2011
    Applicant: UNIVERSITY OF EAST ANGLIA
    Inventors: Ian Michael Wormstone, Lucy Dawes, Julie Ann Eldred, Lixin Wang
  • Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
    Patent number: 6255338
    Abstract: The use of a calcium intracellular store inactivator for inhibiting cell growth is disclosed; for example, thapsigargin or a derivative may be used to inhibit intraocular lens cell growth. Formulations include an emulsion of the compound for coating an IOL, either ex vivo or in vivo.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: July 3, 2001
    Assignees: The University of East Anglia, The Norfolk & Norwich Health Care NHS Trust
    Inventors: George Duncan, Michael Wormstone, Peter Davies, Christopher Liu